Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PreVail: AG-236 in Polycythemia Vera
NCT07859423Phase 3Not yet recruiting
- Sponsor
- Agios Pharmaceuticals
- Start
- Nov 2026
- Primary completion
- Aug 2030
01
Overview
A Phase 3 trial of ALN-TMP in polycythemia vera (PV), sponsored by Agios Pharmaceuticals. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
ALN-TMP
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on NCT07859423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07859423.